Neurocrine Biosciences, Inc.
NBIX
$108.31
$1.311.22%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 2.36B | 2.24B | 2.12B | 1.98B | 1.89B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.36B | 2.24B | 2.12B | 1.98B | 1.89B |
| Cost of Revenue | 765.10M | 716.20M | 666.60M | 623.60M | 604.70M |
| Gross Profit | 1.59B | 1.53B | 1.45B | 1.36B | 1.28B |
| SG&A Expenses | 1.02B | 938.30M | 908.20M | 888.00M | 887.60M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.79B | 1.65B | 1.57B | 1.51B | 1.49B |
| Operating Income | 569.00M | 588.30M | 544.70M | 470.40M | 394.80M |
| Income Before Tax | 486.00M | 521.60M | 446.90M | 469.90M | 332.10M |
| Income Tax Expenses | 144.70M | 135.70M | 107.70M | 100.20M | 82.40M |
| Earnings from Continuing Operations | 341.30 | 385.90 | 339.20 | 369.70 | 249.70 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 341.30M | 385.90M | 339.20M | 369.70M | 249.70M |
| EBIT | 569.00M | 588.30M | 544.70M | 470.40M | 394.80M |
| EBITDA | 596.10M | 614.00M | 569.40M | 492.90M | 416.10M |
| EPS Basic | 3.39 | 3.86 | 3.43 | 3.76 | 2.54 |
| Normalized Basic EPS | 4.10 | 4.22 | 3.93 | 3.41 | 2.86 |
| EPS Diluted | 3.29 | 3.74 | 3.32 | 3.64 | 2.43 |
| Normalized Diluted EPS | 3.98 | 4.08 | 3.79 | 3.29 | 2.77 |
| Average Basic Shares Outstanding | 401.70M | 400.10M | 396.90M | 393.70M | 391.00M |
| Average Diluted Shares Outstanding | 414.70M | 414.10M | 410.90M | 407.20M | 400.70M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
